Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$1.17 - $2.61 $2.04 Million - $4.55 Million
-1,742,123 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.11 - $7.25 $3.76 Million - $12.9 Million
-1,780,889 Reduced 50.55%
1,742,123 $4.32 Million
Q4 2021

Feb 14, 2022

SELL
$5.18 - $7.24 $53,711 - $75,071
-10,369 Reduced 0.29%
3,523,012 $21.2 Million
Q3 2021

Nov 16, 2021

BUY
$5.01 - $7.58 $1.91 Million - $2.9 Million
382,214 Added 12.13%
3,533,381 $23.5 Million
Q2 2021

Aug 16, 2021

BUY
$6.65 - $10.04 $1.42 Million - $2.15 Million
213,985 Added 7.29%
3,151,167 $21 Million
Q1 2021

May 17, 2021

BUY
$9.1 - $19.57 $7.28 Million - $15.6 Million
799,511 Added 37.4%
2,937,182 $27.2 Million
Q4 2020

Feb 16, 2021

BUY
$12.02 - $24.71 $13.5 Million - $27.8 Million
1,124,853 Added 111.06%
2,137,671 $38.4 Million
Q3 2020

Nov 16, 2020

BUY
$4.25 - $14.19 $4.3 Million - $14.4 Million
1,012,818 New
1,012,818 $14.4 Million

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $198M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.